Certa Therapeutics' investigational drug FT011 delivers breakthrough results as a potential novel treatment for serious inflammatory and fibrotic diseases

Research presented today by University of Michigan Medical School highlights FT011's ground-breaking treatment potential from human expression profiles in...

Related Keywords

Melbourne ,Victoria ,Australia ,Michigan ,United States ,Canada ,American ,Matthias Kretzler ,Darren Kelly ,Rare Disease Clinical Research Network ,National Center ,Nephrotic Syndrome Study Network ,Translational Sciences ,University Of Michigan ,Nephcure Kidney International ,University Of Michigan Medical School Professor ,Halpin Foundation ,American Society Of Nephrology ,University Of Michigan Medical School ,Alport Syndrome Foundation ,Michigan Medical School ,Certa Therapeutic ,Kidney Week ,American Society ,Professor Darren Kelly ,Focal Segmental Glomerulosclerosis ,Membranous Nephropathy ,Michigan Medical School Professor ,Lacerta Therapeutics ,Minimal Changes Disease ,Nephrotic Syndrome ,Advancing Translational Sciences ,Non Invasive Surrogates ,